ホーム › 子宮内膜がん › オレゴン › Portland
Portland、ORにおける子宮内膜がんの臨床試験
Portlandとその周辺地域（約30マイル以内）の拠点で、子宮内膜がんに関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
被験者募集中第3相
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
被験者募集中第1/2相
- Research Site, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Oregon Health & Science University (OHSU), Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
被験者募集中第1相
- Site 02, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Portland
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Portland
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
被験者募集中第2相
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Providence Portland Medical Center, Portland
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
被験者募集中第3相
- USOR - NW Cancer Specs P.C., Portland
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
被験者募集中第1相
- Providence Cancer Institute of Oregon, Portland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Oregon Health and Science University, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Providence Cancer Institute, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Compass Oncology - Rose Quarter, Portland
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Oregon Health & Science University, Portland
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Portland
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #121, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Providence Cancer Institute Franz Clinic, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Oregon Health Sciences University, Portland
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
被験者募集中第2相
- Northwest Cancer Specialists, P.C., Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Portland
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
被験者募集中第1/2相
- Oregon Health & Science University, Portland
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
被験者募集中第2/3相
- Northwest Cancer Specialists, Portland
他の都市における子宮内膜がんの試験
- Houston, TX68件の研究
- New York City, NY52件の研究
- Boston, MA50件の研究
- Arlington, VA39件の研究
- Nashville, TN38件の研究
- Los Angeles, CA34件の研究
- St. Louis, MO29件の研究
- Philadelphia, PA28件の研究
- San Antonio, TX27件の研究
- Columbus, OH25件の研究
- Oklahoma City, OK25件の研究
- Chicago, IL25件の研究
Portlandにおける他の研究
- 非小細胞肺癌46件の研究
- がん（全種類）34件の研究
- 乳がん33件の研究
- 前立腺がん33件の研究
- 転移性癌29件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 肺がん26件の研究
- 急性骨髄性白血病25件の研究
- 頭頸部扁平上皮癌19件の研究
- 膵臓がん19件の研究
- 心不全17件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。